Effects of fialuridine on hepatitis B immune globulin pharmacokinetics following orthotopic liver transplant for chronic hepatitis B viral-induced cirrhosis.
McGory
R W
RW
Department of Surgery, University of Virginia Health Sciences, Charlottesville 22908.
Ishitani
M B
MB
Oliveira
W M
WM
Stevenson
W C
WC
Dickson
R C
RC
Caldwell
S H
SH
Pruett
T L
TL
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000628:therapy*; D006512:Hepatitis B Core Antigens / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000302:isolation & purification*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000601:surgery*; D016031:Liver Transplantation / Q000473:pathology; D008297:Male
D000998:Antiviral Agents; D004279:DNA, Viral; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D016756:Immunoglobulins, Intravenous; D001086:Arabinofuranosyluracil; C043457:fialuridine